Arterra Bioscience SpA

Arterra Bioscience SpA maintains a strong liquidity position, with a current ratio of 7.74 and cash and equivalents of EUR 1,342,610. The company's debt-to-equity ratio is 0.07, indicating a conservative capital structure with minimal leverage. Free cash flow of EUR 996,480 and operating cash flow of EUR 1,992,220 support its financial flexibility. The company's profitability is robust, with a return on equity of 15.95% and return on assets of 13.75%. These metrics exceed the typical thresholds for biotechnology firms, suggesting efficient use of equity and assets. Gross profit of EUR 2,882,420 and operating income of EUR 1,797,360 reflect strong operational performance. Arterra Bioscience SpA's revenue is derived from multiple industrial sectors, including cosmetics, agriculture, and nutraceutics. The company's business model is horizontally diversified, reducing exposure to any single market. No specific revenue concentration data is available, but the company's global collaborations suggest a broad geographic footprint. The company's growth trajectory is positive, with a net income of EUR 2,006,280 and revenue of EUR 4,649,470. Capital expenditures of EUR -453,290 indicate a focus on cost efficiency rather than expansion. Analysts have provided a mean price target of EUR 4.20, with a single "buy" recommendation. Risk assessment indicates low liquidity and dilution risks. No immediate filing-based liquidity or dilution flags were detected, and the company's financial structure supports stable operations. The absence of dilution risk is reinforced by the identical basic and diluted shares outstanding of 6,333,034. Recent events include the company's ongoing research and development activities, as well as collaborations with private companies, universities, and research institutes globally. No recent filings or transcripts indicate significant operational or financial changes.